Physician profile
Donna Mckinnon
NPI 1437653425
$2,013.42
in general payments reported to CMS, 2019-2025
21 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.19 · 2022: $42.31 · 2023: $246 · 2024: $1,313 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $530.56 | 2024-2025 | Auvelity, Sunosi |
| Abbvie INC. | $444.54 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $185.38 | 2024 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $178.23 | 2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alexion Pharmaceuticals, INC. | $123.48 | 2024 | Ultomiris |
| Novo Nordisk INC | $97.01 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $56.89 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.83 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $49.27 | 2024-2025 | Trintellix |
| Lilly USA, LLC | $46.86 | 2021-2023 | Mounjaro |
| Pfizer INC. | $44.44 | 2022-2024 | |
| Amgen INC. | $30.75 | 2024-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $25.40 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.56 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $21.72 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $21.57 | 2024 | Korlym |
| Bausch Health US, LLC | $19.70 | 2024 | Aplenzin, Wellbutrin |
| Philips North America LLC | $17.51 | 2024 | (5050) Extended Holter |
| Astellas Pharma US INC | $17.00 | 2024 | Veozah |
| Watermark Medical, INC. | $15.02 | 2024 | |
| Amarin Pharma, INC. | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Mckinnon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.